EUCTR2015-002416-33-FR进行中（未招募）1 期
An interventional, Open-label, single-arm, multicenter, 24 Weeks phase 4 study assessing the Efficacy and Safety of Toujeo in patients with Type 2 Diabetes inadequately controlled with Basal Insulin
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Types 2 diabetes adult patients treated with basal insulin, with or without oral anti-diabetic agents, with or without GLP1 receptor agonist
- •- HbA1c > 7,5 %
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •- Patients with high dose of insulin (>1,2 U/kg)
- •- Use of prandial insulin
- •- Change of dose of antidiabetic drugs within the last 8 weeks
- •- Use of systemic glucocorticoids during at least 2 weeks in the last 12 weeks
研究者
相似试验
进行中（未招募）
不适用
An single arm, open label, interventional multicenter study to assess the efficacy, safety and tolerability of once-monthly administration of intravenous C.E.R.A. for themaintenance of haemoglobin levels in hemodialysis patients with chronic renal anaemia - MIRACLEchronic renal anemiaEUCTR2007-001721-97-ATRoche Pharma (Schweiz) AG200
Unknown
不适用
A study to evaluate efficacy and safety of stem cells in a condition involving severe obstruction of blood vessels of leg, particularly in smokersCTRI/2017/02/007836Stempeutics Research Pvt Ltd164
进行中（未招募）
1 期
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from dimethyl fumarate or fingolimod to ofatumumabMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMultiple sclerosisEUCTR2019-001341-40-NOovartis Pharma AG550
进行中（未招募）
1 期
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approved therapies or fingolimod to ofatumumabMultiple sclerosisMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-001341-40-GRovartis Pharma AG555
进行中（未招募）
1 期
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from dimethyl fumarate or fingolimod to ofatumumabMultiple sclerosisMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-001341-40-PTovartis Pharma AG550